A new study conducted by the National Abdominal Aortic Aneurysm Screening Programme (NAAASP) has determined an endovascular approach to be “safe and effective” in the treatment of abdominal aortic aneurysms.
In addition to this, those treated for infrarenal aneurysms were found to have no aneurysm-related mortality, with a “relatively low” reintervention rate.
Commenting on the significance of the recent research, first author Katherine Stenson from the St George’s Vascular Institute in London said: “At a time when EVAR is under so much scrutiny, it is important that we focus on long-term outcomes and minimise the risk of reinterventions.
“This will have implications for cost-effectiveness and most importantly will have a positive effect on patient safety.”
Specifically, the programme was created to treat men and to reduce the death rate as a result of a ruptured aneurysm.
The findings come at a time when the Abdominal Aortic Aneurysm (AAA) repair devices market is estimated to be worth $2,614 million by 2022, with a growing number of opportunities alongside the expansion of the market.
According to Sriram Radhakrishnan at Allied Market Research, the “rise in the adoption of minimally invasive procedures, favorable reimbursements, and the unpenetrated opportunities in the complex anatomy segment would boost the market growth. In addition, increase in out-of-pocket expenses is expected to boost the adoption of EVAR in the developing regions.”